Given that our results show that the majority of immune checkpoint molecules were associated with high NRF2 expression in ER-positive/HER2-negative breast cancer, we cannot help but speculate that patients whose tumors show high NRF2 expression could be the population who may respond to immune checkpoint inhibitors even though they may not respond to chemotherapy. Here, ERBB2 is linked to breast cancer.